| Cervical cancer |
Hela BALB/c nude mice |
Inhibited Trx/TrxR and glutathione/glutaraldehyde toxin systems to promote oxidative stress, deplete mercaptan content, and active caspase-3 |
(8) |
| Breast cancer |
MCF-7, MDA-MB-231; BALB/c nude mice |
Inhibited cell stemness mediated by the Wnt/β-catenin pathway and inhibit the expression of CD44, MMP7, Cyclin D1, MET, MYC and JUN |
(9) |
| Breast cancer |
MDA-MB-231 |
Increased miR-340-5p and suppresses the SIAH2/HIF-1α pathway, thereby inhibiting epithelial-mesenchymal transition |
(10) |
| Glioblastoma |
U87, U251; BALB/c nude mice |
Increased p53/p21 and Aurora A/PLK1/CDC25C pathway and the expression of p-CDC2 and CCNB1. Inhibited PI3K/AKT/mTOR and upregulate of AMPK/mTOR signaling pathway |
(11) |
| Bladder cancer |
T24, SW78 |
Inhibited the level of lncRNA-HEIH and up-regulated the expression of Bax, caspase-3 |
(12) |
| Hepatocellular carcinoma |
HepG2 |
Exo-sinomenine showed a significantly stronger inhibitory effect in HepG 2 cells |
(7) |
| Hepatocellular carcinoma |
HepG2; Sprague Dawley rat |
Sinomenine and 5-FU exhibited a synergistic inhibitory effect on HepG 2 cells |
(13) |
| Lung cancer |
A549; C57BL/6 mice |
Inhibited the expression of p-ERK1/2, α7-nAChR, SP-1, TTF-1, and increase the expression of EGR1 |
(14) |
| Ovarian cancer |
HeyA8-MDR |
Inhibited P-CDK1 (Thr161) and P-H3 (Ser 10), downregulated CDK1, PLK1 and BUB1, and inhibited G2/M transition |
(15) |
| Breast cancer |
MDA-MB-231, MCF-71 |
Inhibited the activation of PI3K/Akt/mTOR signaling pathway and inhibited the express of MMP-2 and MMP-9 |
(16) |
| Lung cancer |
A549, H1299 |
Inhibited the expression of miR-21, MMP-2, MMP-9, EMMPRIN/CD147, and Vimentin, increase the express of RECK, TIMP-1/-2 and E-cadherin |
(17) |
| Non-small cell lung cancer |
HCC827, H460, H23, H1650, H1299, H1975; female athymic nude mice |
Inhibited AKT, kinase S6, and thus inhibited HK2-mediated glycolysis, and increase the expression of cleaved-caspase-3, cleaved-PARP, increase the expression of Cytochrome C and Bax |
(18) |
| Ovarian cancer |
HOEpiC, A2780, Caov3, Hey, OVCAR3, SKOV3 |
Down-regulated HOST2, Cyclin D1, CDK4, CDK6, Bcl-2, and Bax caspase-3 was up-regulated to induce G0/G1 stagnation |
(19) |
| Breast cancer |
MDA-MB-231, MCF-7 |
Increased the expression of miR-29/PDCD4, thereby blocking the JNK and MEK/ERK pathways. Increased the expression of caspase-3/-9, p16. Inhibited the expression of PCNA, Cyclin D1, and CDK4 |
(20) |
| Breast cancer |
BALB/c nude mice |
Regulated IL-8/CXCR1 and c-Fos/NFATc1 signaling to inhibit osteolysis in breast cancer |
(21) |
| Cervical cancer |
HeLa; female BALB/c nude mice |
Suppressed the expression of Ku80 and Rad51 and enhanced radiotherapy sensitivity |
(22) |
| Breast cancer |
MDA-MB-231; BALB/C male nude mice |
Inhibited NF-κB/SHh signaling pathway and inhibited the expression of Cyclin D1, Bcl-2, MMP-2 and IL-11 |
(23) |
| Breast cancer |
Virgin female Sprague Dawley rats |
Inhibited the microglial JAK2/STAT3 signaling pathway and neuronal CAMKII/CREB cascade in the rat model to alleviate cancer-induced bone pain |
(24) |
| Renal carcinoma |
Human renal cell adenocarcinoma |
Inhibited PI3K/AKT/mTOR signaling pathway to promoted autophagy and inhibited the expression of Ki-67 and PCNA |
(25) |
| Renal carcinoma |
Clear cell renal cell carcinoma |
Inhibited the expression of TGF-β, Snail1, Twist and Smad signaling pathways and then inhibit epithelial-mesenchymal transition |
(26) |
| Breast cancer |
MDA-MB-231, RAW246.7, 4T1; female BALB/c nude mice |
Inhibited the expression of IL-6, MMP9, CD44, and Sox-2; increased the expression of TIMP-1, TIMP-2, and inhibited epithelial-mesenchymal transition |
(27) |
| Hepatocellular carcinoma |
HepG2, Hep3B |
Arrested hepatocellular carcinoma cell cycle at G0/G1 phase, induces cell death and growth inhibition through AMPK/STAT3 signaling pathway |
(28) |
| Multiple myeloma |
Multiple myeloma cells |
YL064 may prevent the interaction of STAT3 with phosphorylated tyrosine residues on cytoplasmic receptor kinases through targeting the SH 2 domain of STAT3 |
(29) |
| Hepatocellular carcinoma |
SK-Hep1, Hepa1-6p1 |
Inhibited ERK1/2/MMP2/9 signaling pathway and inhibit the growth and invasion of oncocytes |
(30) |
| Colon cancer |
LoVo |
Sinomenine enhanced the inhibitory effect of 5-FU on the proliferation and apoptosis of colon cancer cells, and did not increase the side effects of chemotherapy |
(31) |
| Gastric cancer |
MKN-28, SGC-709, BGC823, HGC-27; male BALB/c-nu/nu mice |
Sinomenine reduced thymidylate synthase mRNA accumulation and enhances the 5-FU-mediated mitochondrial apoptosis pathway |
(32) |
| Hepatic carcinoma |
Hep3B, SMMC7721, HepG2, and so on; male BALB/c athymic nude mice |
Increased survivin, p21, cytochrome C and increase the release of Omi/HtrA2 from mitochondria into cytoplasm to induce apoptosis |
(33) |
| Esophagus cancer |
Eca109 and EC9706; BALB/c nude mice |
Induced G2/M arrest, promoting radiation-induced apoptosis and inhibited DNA double-strand break repair |
(34) |
| Glioblastoma |
U87, U251 |
Promoted p53 expression and its acetylation, reduced sirtuin 1 expression, and induced G0/G1 cell cycle arrest and apoptosis |
(35) |
| Mantle cell lymphoma |
Jeko-1 |
Inhibited Akt/mTOR/P70S6K pathway and promote cell apoptosis |
(36) |
| Osteosarcoma |
Human osteosarcoma cells, U2OS |
Inhibited CXCR4-STAT3 pathway and osteoclastgenesis mediated bone destruction and inhibit invasion and metastasis |
(37) |
| Esophagus cancer |
Eca-109 |
Promoted the progression of mitochondrial apoptosis induced by 5-FU, and the drug combination does not increase the side effects of chemotherapy |
(38) |
| Myeloma |
U266, MM1.S, BMSCs HS-5, Hela |
Suppressed the nuclear translocation of STAT3 between its target gene Cyclin D1 and Mcl-1 |
(39) |
| Thyroid cancer |
HTori-3, BCPAP, TPC-1 |
Enhanced the sensitivity of radiotherapy. Inhibited the ratio of Bcl-2 to Bax, and increase the expression of Fas, p21, p-ATM, p-Chk1, p-Chk2 and p53 |
(40) |
